284 related articles for article (PubMed ID: 25030803)
41. Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia.
Loebel AD; Siu CO; Cucchiaro JB; Pikalov AA; Harvey PD
CNS Spectr; 2014 Apr; 19(2):197-205. PubMed ID: 24330860
[TBL] [Abstract][Full Text] [Related]
42. A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression.
Brown ES; Park J; Marx CE; Hynan LS; Gardner C; Davila D; Nakamura A; Sunderajan P; Lo A; Holmes T
Neuropsychopharmacology; 2014 Nov; 39(12):2867-73. PubMed ID: 24917198
[TBL] [Abstract][Full Text] [Related]
43. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
Weiser M; Levi L; Burshtein S; Hagin M; Matei VP; Podea D; Micluția I; Tiugan A; Păcală B; Grecu IG; Noy A; Zamora D; Davis JM
J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
[TBL] [Abstract][Full Text] [Related]
44. A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.
Haig GM; Bain EE; Robieson WZ; Baker JD; Othman AA
Am J Psychiatry; 2016 Aug; 173(8):827-35. PubMed ID: 26940805
[TBL] [Abstract][Full Text] [Related]
45. Compensatory cognitive training for people with first-episode schizophrenia: results from a pilot randomized controlled trial.
Mendella PD; Burton CZ; Tasca GA; Roy P; St Louis L; Twamley EW
Schizophr Res; 2015 Mar; 162(1-3):108-11. PubMed ID: 25631454
[TBL] [Abstract][Full Text] [Related]
46. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.
Farokhnia M; Sabzabadi M; Pourmahmoud H; Khodaie-Ardakani MR; Hosseini SM; Yekehtaz H; Tabrizi M; Rezaei F; Salehi B; Akhondzadeh S
Psychopharmacology (Berl); 2014 Feb; 231(3):533-42. PubMed ID: 24013610
[TBL] [Abstract][Full Text] [Related]
47. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
Akhondzadeh S; Mohammadi N; Noroozian M; Karamghadiri N; Ghoreishi A; Jamshidi AH; Forghani S
Schizophr Res; 2009 Feb; 107(2-3):206-12. PubMed ID: 18789844
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial.
Sepehrmanesh Z; Heidary M; Akasheh N; Akbari H; Heidary M
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Mar; 82():289-296. PubMed ID: 29126981
[TBL] [Abstract][Full Text] [Related]
49. Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.
Kelly DL; Sullivan KM; McEvoy JP; McMahon RP; Wehring HJ; Gold JM; Liu F; Warfel D; Vyas G; Richardson CM; Fischer BA; Keller WR; Koola MM; Feldman SM; Russ JC; Keefe RS; Osing J; Hubzin L; August S; Walker TM; Buchanan RW
J Clin Psychopharmacol; 2015 Aug; 35(4):374-81. PubMed ID: 26082974
[TBL] [Abstract][Full Text] [Related]
50. An optimal combination of MCCB and CANTAB to assess functional capacity in older individuals with schizophrenia.
Kumar S; Mulsant BH; Tsoutsoulas C; Ghazala Z; Voineskos AN; Bowie CR; Rajji TK
Int J Geriatr Psychiatry; 2016 Oct; 31(10):1116-23. PubMed ID: 27428251
[TBL] [Abstract][Full Text] [Related]
51. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH
Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
[TBL] [Abstract][Full Text] [Related]
52. Measurement and Treatment Research toImprove Cognition in Schizophrenia Consensus Cognitive Battery: validation of the Japanese version.
Kaneda Y; Ohmori T; Okahisa Y; Sumiyoshi T; Pu S; Ueoka Y; Takaki M; Nakagome K; Sora I
Psychiatry Clin Neurosci; 2013 Apr; 67(3):182-8. PubMed ID: 23581870
[TBL] [Abstract][Full Text] [Related]
53. Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial.
Moazen-Zadeh E; Bayanati S; Ziafat K; Rezaei F; Mesgarpour B; Akhondzadeh S
J Psychopharmacol; 2020 May; 34(5):506-513. PubMed ID: 32122230
[TBL] [Abstract][Full Text] [Related]
54. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
[TBL] [Abstract][Full Text] [Related]
55. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study.
Kane JM; Yang R; Youakim JM
Schizophr Res; 2012 Mar; 135(1-3):116-22. PubMed ID: 22178084
[TBL] [Abstract][Full Text] [Related]
56. The effect of anticholinergic burden on cognitive and daily living functions in patients with schizophrenia.
Kim SJ; Jung D; Shim JC; Moon JJ; Jeon DW; Kim YN; Seo YS; Jung SS; Seo BJ; Kim JE
Asian J Psychiatr; 2019 Dec; 46():111-117. PubMed ID: 31654923
[TBL] [Abstract][Full Text] [Related]
57. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group.
Borison RL; Arvanitis LA; Miller BG
J Clin Psychopharmacol; 1996 Apr; 16(2):158-69. PubMed ID: 8690831
[TBL] [Abstract][Full Text] [Related]
58. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
[TBL] [Abstract][Full Text] [Related]
59. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
Ghajar A; Gholamian F; Tabatabei-Motlagh M; Afarideh M; Rezaei F; Ghazizadeh-Hashemi M; Akhondzadeh S
Hum Psychopharmacol; 2018 Jul; 33(4):e2662. PubMed ID: 29901250
[TBL] [Abstract][Full Text] [Related]
60. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.
Josiassen RC; Joseph A; Kohegyi E; Stokes S; Dadvand M; Paing WW; Shaughnessy RA
Am J Psychiatry; 2005 Jan; 162(1):130-6. PubMed ID: 15625211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]